94064-00-3

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 15804-19-0 quinoxaline-2,3-dione 
• 2213-63-0 2,3-dichloroquinoxaline 
• 106-49-0 p-toluidine 

Downstream Products

• 1408230-82-9 3-bromo-2-tert-butyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 73040-45-6 2-phenyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-81-8 3-(phenylethynyl)-N-p-tolylquinoxalin-2-amine 
• 1408230-59-0 2-(1-p-tolyl-1H-pyrrolo[2,3-b]quinoxalin-2-yl)ethanol 
• 1408230-60-3 1-[1-(4-methylphenyl)-1H-pyrrolo[2,3-b]quinoxalin-2-yl]cyclohexanol 
• 1408230-61-4 4-(1-p-tolyl-1H-pyrrolo[2,3-b]quinoxalin-2-yl)butanenitrile 
• 1408230-62-5 2-butyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-63-6 2-tert-butyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-64-7 1,2-di-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-66-9 2-butyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-68-1 1-(1-p-tolyl-1H-pyrrolo[2,3-b]quinoxalin-2-yl)ethanol 
• 1408230-70-5 2-hexyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-72-7 2-decyl-1-p-tolyl-1H-pyrrolo[2,3-b]quinoxaline 
• 1408230-78-3 N-p-tolyl-3-((trimethylsilyl)ethynyl)quinoxalin-2-amine 

Relevant academic research and scientific papers

Synthesis and Antimicrobial Activity of Quinoxaline Based 1,2,3-Triazoles

Abstract: Synthesis and characterization of novel quinoxaline-1,2,3-triazole hybridheterocyclic derivatives have been carried out, and their antimicrobial activityhas been tested. Antibacterial and antifungal studies of the synthesizedcompounds have demonstrated high to moderate activity against the testedpathogens for most of those. Several products have been determined to be potentantimicrobial agents at concentrations of 75 and 100 μg/mL as compared to thestandard drug Gentamicin.

Ligand-free MCR for linking quinoxaline framework with a benzimidazole nucleus: A new strategy for the identification of novel hybrid molecules as potential inducers of apoptosis

We report a true MCR involving the reaction of N-(prop-2-ynyl)quinoxalin-2- amine derivatives with 2-iodoanilines and tosyl azide in the presence of 10 mol% of CuI and Et3N in DMSO to afford the pre-designed hybrid molecules containing quinoxaline framework linked with a benzimidazole nucleus. The MCR proceeds in the absence of any ligand and/or lateral addition of the catalyst/base affording products within 30 min in good yields, some of which showed encouraging apoptosis inducing properties in zebrafish. This journal is the Partner Organisations 2014.

Ligand/PTC-free intramolecular Heck reaction: Synthesis of pyrroloquinoxalines and their evaluation against PDE4/luciferase/oral cancer cell growth in vitro and zebrafish in vivo

A series of 1,3-disubstituted pyrrolo[2,3-b]quinoxalines has been designed for the potential inhibition of PDE4 without inhibiting luciferase. A ligand/PTC (phase transfer catalyst) free intramolecular Heck cyclization strategy was used to prepare these compounds, some of which showed significant inhibition of PDE4B (IC50 ≈ 5-14 μM) and growth inhibition of oral cancer cells (CAL 27) but not inhibition of luciferase in vitro. They also showed acceptable safety profiles but no apoptosis in zebrafish embryos.

AlCl3 induced C-N bond formation followed by Pd/C-Cu mediated coupling-cyclization strategy: Synthesis of pyrrolo[2,3-b]quinoxalines as anticancer agents

AlCl3 facilitated C-N bond forming reaction between 2,3-dichloroquinoxaline and anilines affording a convenient method for the preparation of N-aryl substituted 3-chloroquinoxalin-2-amines. A related N-benzyl derivative, however, was prepared via a conventional method. These N-alkyl/aryl substituted 3-chloroquinoxalin-2-amines on coupling with terminal alkynes in toluene under Pd/C-Cu catalysis afforded a range of 1,2-disubstituted pyrrolo[2,3-b]quinoxalines within 3-5 h in good to excellent yields. Some of the compounds synthesized showed promising anti-proliferative properties when tested in vitro against two cancer cell lines. Docking studies indicated that these molecules interact well with human Akt in silico.